Medicare Enrolled
Dr. Talha Badar, M.D
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Badar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Badar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Badar
Dr. Talha Badar is a hematology & oncology specialist in Jacksonville, FL, with 12 years of NPI registration. Based on federal Medicare data, Dr. Badar performed 68,706 Medicare services across 2,423 unique beneficiaries.
Between the years covered by Open Payments, Dr. Badar received a total of $18,297 from 10 pharmaceutical and/or device companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Badar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 12% volume in FL
$18,297 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 146204 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗68,706
Medicare services
Top 12% in FL for hematology & oncology
2,423
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,726 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,000 | $41 | $195 |
| Nivolumab injection (Opdivo) | 9,320 | $24 | $114 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,950 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
6,775 | $2 | $11 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
6,120 | $38 | $189 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
6,120 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,572 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $18 | $90 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,830 | $0 | $3 |
| Anti-nausea injection (ondansetron/Zofran) | 1,552 | $0 | $5 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,480 | $36 | $137 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
1,330 | $23 | $182 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,020 | $22 | $192 |
| Injection, atropine sulfate, 0.01 mg | 805 | $0 | $1 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
630 | $3 | $9 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
459 | $12 | $216 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
401 | $94 | $450 |
| Injection, irinotecan, 20 mg | 341 | $2 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 330 | $1 | $8 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
296 | $100 | $869 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
264 | $2 | $29 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
193 | $20 | $135 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
186 | $2 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 179 | $3 | $36 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
156 | $96 | $452 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 136 | $133 | $490 |
| Injection, leucovorin calcium, per 50 mg | 131 | $3 | $23 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
127 | $11 | $102 |
| Injection, potassium chloride, per 2 meq | 120 | $0 | $17 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
100 | $22 | $233 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
98 | $2 | $82 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $48 | $446 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
88 | $22 | $212 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
84 | $10 | $114 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
76 | $1 | $17 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
66 | $1 | $38 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
63 | $55 | $352 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
63 | $26 | $200 |
| New patient office visit, complex (60-74 min) | 63 | $162 | $891 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
62 | $49 | $426 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
55 | $6 | $52 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
53 | $16 | $154 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
38 | $25 | $345 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
33 | $15 | $143 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
31 | $133 | $993 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
31 | $1 | $80 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
22 | $143 | $604 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
20 | $92 | $487 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
18 | $27 | $600 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
15 | $43 | $370 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $106 | $630 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.2% high complexity
86.2% medium
1.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$18,297
Total received (2018-2024)
Avg $2,614/year across 7 years
Top 27% in FL for hematology & oncology
10
Companies
25
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,979 (49.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,091 (44.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,227 (6.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,482
2023
$10,420
2022
$55
2021
$5,250
2020
$216
2019
$462
2018
$411
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$8,091
MorphoSys, US Inc.
$3,914
Takeda Pharmaceuticals U.S.A., Inc.
$3,222
AstraZeneca Pharmaceuticals LP
$1,424
BeiGene USA, Inc.
$675
Celgene Corporation
$499
SOBI, INC
$200
Ipsen Biopharmaceuticals, Inc
$125
Janssen Biotech, Inc.
$91
AstraZeneca UK Limited
$55
Top 3 companies account for 83.2% of total payments
Associated products mentioned in payments ›
Abraxane · BESPONSA · BRUKINSA · CALQUENCE · CIBINQO · ERLEADA · ICLUSIG · Onivyde · Pomalyst · Revlimid · TAGRISSO · VONJO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (49%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $27 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
104
Per 100K population
10.3
County median income
$68,447
Nearest hospital
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Badar is a mixed practice specialist, with above-average Medicare volume (top 12% in FL), with consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Badar experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Badar performed 12,000 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Badar receive payments from pharmaceutical companies?
Yes. Dr. Badar received a total of $18,297 from 10 companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Badar's costs compare to other hematology & oncology specialists in Jacksonville?
Dr. Badar's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Badar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jacksonville
Browse hematology & oncology specialists in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
MorphoSys, US Inc. Payments to Doctors
See all physicians who received payments from MorphoSys, US Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology